3SGJ Surges to Record High as China’s Innovation‑Drug Policy Boosts Momentum
3SGJ’s record surge reflects China’s new commercial‑insurance innovation‑drug policy, offering investors a chance to tap the growing biologics market—find out how this stock could reshape its future.
3 minutes to read